Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 + Sintilimab vs Interferon in Resected Acral Melanoma
NCT04277663Phase 3Terminated
- Sponsor
- Innovent Biologics
- Start
- Apr 2020
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of IBI310, sintilimab in acral lentiginous melanoma (ALM), sponsored by Innovent Biologics. Started Apr 2020; status: terminated.
02
Drugs
IBI310sintilimab
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT04277663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04277663.